Real-World Studies
Patient-reported outcomes as non-muscle-invasive bladder cancer clinical trial endpoints
Toumazos et alBJU International
A cross-sectional analysis of 94 interventional non-muscle-invasive bladder cancer (NMIBC) clinical trials registered on ClinicalTrials.gov between 1994 and 2025 demonstrates that patient-reported outcomes (PROs) remain underutilized as trial endpoints. Overall, only 21 trials (22%) incorporated PROs, with these measures designated as primary endpoints in just 3% and secondary endpoints in 20% of studies. PRO incorporation rates exhibited minimal change over the evaluated time period.
Among trials capturing PROs, the most frequently employed assessment tools were the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), used in 48% of PRO-inclusive studies, and the EORTC QLQ-NMIBC24 module, utilized in 43%. Trials integrating PROs were characterized by significantly larger median projected patient enrollments (median [IQR] 166 [461] vs 46 [101] patients, P = 0.002) and trended toward higher rates of randomized controlled trial designs (62% vs 41%, P = 0.057). No statistically significant difference in PRO utilization was observed across funding types (industry-sponsored vs cooperative group or federally funded). Despite regulatory guidance from the FDA and advocacy from patient organizations emphasizing the value of capturing the holistic patient experience, PRO integration in NMIBC interventional trials remains limited, underscoring the need for standardized PRO tool harmonization and broader implementation in trial protocols.
Key Takeaways
- Only 22% (21 of 94) of interventional non-muscle-invasive bladder cancer (NMIBC) clinical trials incorporated patient-reported outcomes (PROs), with PROs serving as primary endpoints in 3% and secondary endpoints in 20% of trials.
- Trials integrating PRO endpoints had significantly larger anticipated enrollment sizes than those without PROs (median 166 vs 46 patients, P = 0.002), with the EORTC QLQ-C30 (48%) and EORTC QLQ-NMIBC24 (43%) being the most frequently utilized instruments.
Read the original sourceBJU International
